# Signals Article on Putative Target P01911 for Crohn Disease
Background
The protein encoded by the putative target P01911 has emerged as a candidate of interest in the study of Crohn disease, a type of inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract. Preliminary findings suggest that P01911 may play a role in the inflammatory processes associated with Crohn disease, highlighting its potential as a therapeutic target. Given the complexity of Crohn disease, further investigation into the molecular mechanisms involving this protein is essential for developing effective treatment strategies.Data-mining rationale
In our analysis, we employed the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "Crohn disease" against 133 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:P01911 was identified as being present in several expression-profiling studies, yet notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in Crohn disease and underscores the need for further exploration.Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. Consequently, previous analyses may not have accurately captured the expression dynamics of P01911 in the context of Crohn disease. The lack of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in Crohn disease.Reasoning for further validation
To substantiate the potential role of P01911 in Crohn disease, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including P01911, by quantitative PCR (qPCR) in an independent cohort of Crohn disease patients to confirm expression patterns. 3. Investigate the tissue specificity of P01911 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in gastrointestinal tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize P01911 within known biological pathways related to inflammation and Crohn disease. 5. If validation is achieved, assess the druggability of P01911 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.References
- [UniProt: P01911](https://www.uniprot.org/uniprot/P01911)
- [NCBI GEO Accession GDS:200298981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200298981)
- [NCBI GEO Accession GDS:200298133](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200298133)
- [NCBI GEO Accession GDS:200242140](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200242140)
- [NCBI GEO Accession GDS:200186963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200186963)
- [NCBI GEO Accession GDS:200244938](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200244938)